| http://www.w3.org/ns/prov#value | - All patients starting therapy with Altoprev??, or whose dose of Altoprev?? is being increased, should be advised of the risk of myopathy, including rhabdomyolysis, and told to report promptly any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing Altoprev. Altoprev therapy should be discontinue
|
